Iterum Therapeutics PLC (ITRM)
Official siteBIOTECHNOLOGY
Last updated: Nov 06, 2026 at 4:00 PM ET
Earnings
Performance (10Y)
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the 50-day average is below the 200-day average. The 14-day RSI is 25.8, below 30, the oversold line.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about ITRM
News
No news available
Company news will appear here when available
ITRM Valuation
- P/B
- -0.2x
ITRM Profitability: Margins, ROIC and FCF
Iterum Therapeutics Competitors
Peers by sector and size for Iterum Therapeutics (ITRM) include Flora Growth, Mobile-health Network Solutions Class A Ordinary Shares and Kairos Pharma.
Sector: Healthcare
ITRM Earnings: Beat Rate
- Beat rate
- 4 of 8 quarters (50.0%)
- Average surprise
- 7.9%
ITRM Earnings Call
The latest ITRM earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptUpdated Mar 12, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About ITRM
Does ITRM pay dividends?
Iterum Therapeutics PLC (ITRM) does not currently pay a regular dividend.
ITRM pages: Overview, Financials
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.